At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.
To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term.
A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution.
FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice.
The American College of Obstetrics and Gynecology said it will no longer be accepting federal funding.
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.
Brown University has reached an agreement with the Trump administration to restore the university’s federal funding for medical and health sciences research.
President Donald Trump signed an executive order mandating that his appointees will review all funding announcements and grant awards to “verify that each grant dollar benefits Americans instead of lining grantees’ pocketbooks or furthering causes that damage America.”
A study led by researchers at the University of Pennsylvania has found that binary (yes/no) voting at the FDA Oncologic Drugs Advisory Committee can accurately capture the committee members’ perspectives in most cases.
